KAYRROS
31.3.2020 08:07:10 CEST | Business Wire | Press release
Kayrros SAS, a leading global asset observation platform, is today announcing the latest findings from its technology to track, quantify and attribute global methane emissions. Kayrros uses data from the European Space Agency (ESA) Copernicus program’s Sentinel-5 Precursor satellite and has built a detection and quantification model to trace emissions back to their source. These unique and comprehensive findings show that:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200330005801/en/
- Methane emissions can now be detected and quantified at an asset level on a global scale , which represents a major step-change in the ability to work towards the reduction of man-made emissions.
- The data shows that there are around 100 high volume-emitting events at any one time around the world. Together, in the course of one year, they are releasing 20 megatons of methane which is equivalent to 1.8 gigatons of CO2 in the first twenty years .1
- Through its proprietary attribution model, Kayrros can identify that around one half of that CO2 equivalent in the first twenty years, or 1 gigaton, are in regions with heavy industry such as oil & gas, coal mining, etc . This is equivalent to the total annual CO2 emissions of Germany and France together.2
Kayrros is a leading Earth observation analytics player able to combine extensive mapping of assets, deep sectoral understanding, and complex machine learning algorithms as well as detection and quantification models in order to identify the missing link between concentrations and emissions.
“What we are announcing today is ground-breaking,” says Antoine Rostand, CEO of Kayrros. “The combination of Sentinel 5-P satellite imagery and Kayrros technology represents a world first in the ability to track and attribute these substantial individual methane leaks. The good news is most of these are man-made and can easily be addressed through action by individual companies, governments and regulators.”
Claus Zehner, Sentinel 5-P Mission manager at ESA, says, “We are pleased to support Kayrros in its use of the Sentinel 5-P data to develop new tools for global methane emissions monitoring. Europe’s investment into satellite technology is ever more crucial if it can support the reduction of global emissions and slow down climate change.”
Kayrros has presented its methodology and approach to the European Commission and its Directorate General for Energy. The upcoming European strategy to reduce methane emissions will include a methodology for methane measurement and quantification that builds on Copernicus and other satellite data for detection and validation. Kayrros remains in dialogue with the European Commission about its work.
Kayrros has also worked with LSCE 3 scientists on Sentinel 5-P imagery to identify and quantify thousands of major methane plumes from various sources around the world. Thomas Lauvaux from the LSCE comments, “To date, only a handful of these large anthropogenic sources have been documented. To expand this, as Kayrros technology does, constitutes a significant step toward mitigating methane emissions around the globe, a significant contributor to climate change, with the support of operators who now have the required information to take immediate action.”
Antoine Rostand emphasizes, “The consequences of these findings are immense, as they enable individual companies in the energy sector to identify and address methane leaks across their networks. Equally, governments and regulators should take note that access to such detailed emissions data will drastically change their ability to hold emitters accountable and potentially reverse the trend of ever-increasing emissions rates.”
This technology is now available to the industry for immediate implementation.
About Kayrros
Kayrros is the leading global asset observation platform worldwide. Harnessing satellite imagery and unconventional data with machine learning, natural language processing and advanced mathematics, Kayrros delivers focused monitoring and measurement of energy and natural resource activity around the world. With access to data on more than 200,000 industry assets, Kayrros customers can observe individual or multiple assets in proprietary or multi-client workflows to analyse industrial and environmental performance for the insight needed to make optimal operational and financial decisions. For more information, please visit www.kayrros.com .
1 |
1 ton of methane is equivalent to 84 tons of CO2 in the first 20 years (Environment Defense Fund ). |
|
2 |
Based on World bank Databank on CO2 emissions for 2014 |
|
3 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005801/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
